Last month, Taiwanese-based Bora Pharmaceuticals completed their acquisition of leading generics manufacturer Upsher-Smith, as the company looks to further its expansion into the U.S.

It seems that generic medicines can’t assume market dominance either. In a recent survey by GlobalData, nearly 40% of healthcare professionals said they would choose brand-name drugs over generics if cost was not a factor - particularly in countries (like Japan, Spain, and Italy) where brand loyalty is particularly strong.

Lenmeldy, a gene therapy for metachromatic leukodystrophy (MLD), has been priced at $4.25 million in the U.S., becoming the world's most expensive drug. This one-time treatment by Orchard Therapeutics, now part of Kyowa Kirin, is the first FDA-approved therapy for children with early-onset MLD.

J&J has filed a lawsuit against a former employee - Andrew Brackhill - accusing him of illicitly downloading and taking thousands of sensitive documents with him to Pfizer.

Pfizer reportedly paid as much as $7 million for a 60-second commercial, leading to a finale which promoted its latest cancer initiative - LetsOutDoCancer.com.

Look out for the keynote by Richard Francis, CEO of Teva Pharmaceuticals, where he’ll discuss how Teva’s focus on innovation, sustaining its generics powerhouse, and its focus on growth engines is fuelling the company’s Pivot to Growth Strategy to build a rich portfolio of innovative medicines.

On the back of their 40th Anniversary event in Gamsen, Germany, Valsynthese posted their genuinely informative and entertaining short video that tells the company’s story from the perspective of its people.